Latest Insider Transactions at Artivion, Inc. (AORT)
This section provides a real-time view of insider transactions for Artivion, Inc. (AORT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARTIVION, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARTIVION, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
47,376
-18.89%
|
$2,131,920
$45.13 P/Share
|
|
Nov 21
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Exercise of conversion of derivative security
|
Direct |
47,376
+25.58%
|
$663,264
$14.74 P/Share
|
|
Nov 20
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
15,276
-9.42%
|
$672,144
$44.24 P/Share
|
|
Nov 20
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Exercise of conversion of derivative security
|
Direct |
3,388
+3.51%
|
$47,432
$14.74 P/Share
|
|
Nov 18
2025
|
Elizabeth A Hoff Director |
SELL
Open market or private sale
|
Direct |
4,200
-13.38%
|
$189,000
$45.1 P/Share
|
|
Nov 17
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,394
-3.77%
|
$287,730
$45.17 P/Share
|
|
Nov 17
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,394
+3.63%
|
$185,426
$29.62 P/Share
|
|
Nov 17
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,394
-3.12%
|
$287,730
$45.17 P/Share
|
|
Nov 17
2025
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,394
+3.02%
|
$185,426
$29.62 P/Share
|
|
Nov 17
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
6,000
-4.24%
|
$270,000
$45.73 P/Share
|
|
Nov 14
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,393
-3.77%
|
$287,685
$45.0 P/Share
|
|
Nov 14
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,393
+3.63%
|
$185,397
$29.62 P/Share
|
|
Nov 14
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,393
-3.12%
|
$281,292
$44.67 P/Share
|
|
Nov 14
2025
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,393
+3.02%
|
$185,397
$29.62 P/Share
|
|
Nov 13
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,482
-2.4%
|
$156,690
$45.86 P/Share
|
|
Nov 13
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,563
-3.2%
|
$295,335
$45.86 P/Share
|
|
Nov 13
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
4,993
-8.1%
|
$224,685
$45.86 P/Share
|
|
Nov 13
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
5,761
-3.41%
|
$259,245
$45.86 P/Share
|
|
Nov 13
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
34,210
-4.1%
|
$1,539,450
$45.86 P/Share
|
|
Nov 11
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-5.58%
|
$460,000
$46.18 P/Share
|
|
Nov 11
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.29%
|
$110,000
$11.03 P/Share
|
|
Nov 10
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,960
-1.72%
|
$130,240
$44.62 P/Share
|
|
Nov 10
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
2,566
-4.0%
|
$112,904
$44.62 P/Share
|
|
Nov 10
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,789
-1.22%
|
$78,716
$44.62 P/Share
|
|
Nov 10
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,373
-1.62%
|
$148,412
$44.62 P/Share
|
|
Nov 10
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
17,580
-2.06%
|
$773,520
$44.62 P/Share
|
|
Aug 27
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
18,200
-22.09%
|
$800,800
$44.02 P/Share
|
|
Aug 27
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Exercise of conversion of derivative security
|
Direct |
18,200
+18.09%
|
$200,200
$11.03 P/Share
|
|
Aug 25
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-5.49%
|
$440,000
$44.37 P/Share
|
|
Aug 25
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.2%
|
$110,000
$11.03 P/Share
|
|
Aug 15
2025
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-1.44%
|
$525,000
$42.32 P/Share
|
|
Aug 12
2025
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,802
-4.92%
|
$464,486
$43.67 P/Share
|
|
Aug 12
2025
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,802
+4.69%
|
$280,852
$26.24 P/Share
|
|
Aug 12
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
23,356
-6.13%
|
$1,004,308
$43.01 P/Share
|
|
Aug 12
2025
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
16,975
+7.99%
|
$441,350
$26.24 P/Share
|
|
Aug 08
2025
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
7,992
-5.17%
|
$303,696
$38.49 P/Share
|
|
Aug 08
2025
|
Amy Horton VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,992
+4.91%
|
$231,768
$29.62 P/Share
|
|
Jun 17
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
15,000
-9.63%
|
$435,000
$29.5 P/Share
|
|
Jun 13
2025
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
26,132
-6.72%
|
$731,696
$28.45 P/Share
|
|
May 27
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
8,748
-4.67%
|
$253,692
$29.0 P/Share
|
|
May 23
2025
|
Anthony B. Semedo Director |
SELL
Open market or private sale
|
Direct |
2,600
-7.29%
|
$72,800
$28.47 P/Share
|
|
May 22
2025
|
Marna P Borgstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+11.41%
|
-
|
|
May 22
2025
|
Anthony B. Semedo Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+13.09%
|
-
|
|
May 22
2025
|
Jon W Salveson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+4.65%
|
-
|
|
May 22
2025
|
Thomas F Ackerman Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+4.05%
|
-
|
|
May 22
2025
|
Daniel J Bevevino Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+4.04%
|
-
|
|
May 22
2025
|
Jeffrey H Burbank Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+10.52%
|
-
|
|
May 22
2025
|
Elizabeth A Hoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+16.77%
|
-
|
|
May 22
2025
|
James Bullock Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,325
+8.44%
|
-
|
|
May 21
2025
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
9,926
-5.03%
|
$287,854
$29.0 P/Share
|